spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018
Westin Boston Waterfront, Boston, Massachusetts

Cambridge Healthtech Institute's Fourteenth Annual Biomarkers and Immuno-Oncology World Congress, now in Boston, is our longest-running event dedicated to all areas of biomarker research and development spanning the pharmaceutical and diagnostic pipelines. With the promising developments in immuno-oncology over the past years, much of the biomarker R&D has shifted to discovery and development of predictive biomarkers for immunotherapy patient stratification, using biomarkers to choose rational combination immunotherapy, and applying immune profiling to predict and monitor response to immunotherapy. The Immuno-Oncology Biomarkers stream will address predictive biomarkers and companion diagnostics, as well as immune profiling and immune monitoring. The Immunotherapy stream will address the two biggest challenges in pharmaceutical IO programs: designing rational combination immunotherapies and strategies to address intrinsic and acquired resistance. Finally, a new track on Digital Biomarkers will cover the clinical utility of biosensors, wearables and mobile health, and their emerging applications in drug development.

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies. Now in its fourteenth year, the Biomarkers and Immuno-Oncology World Congress is the leading annual meeting dedicated to biomarkers, diagnostics, and immuno-oncology research and implementation that consistently delivers a cutting-edge agenda, 400+ senior delegates, and a sold-out exhibit hall.

Please join us in Boston for comprehensive scientific coverage and unparalleled networking opportunities at the Fourteenth Annual Biomarkers and Immuno-Oncology World Congress 2018!

Visit the event page often for updates: www.BiomarkerWorldCongress.com

-Contact Details 

Cambridge Healthtech Institute

250 First Avenue, Suite 300

Needham, MA 02494

T: 781-972-5400

F: 781-972-5425

E: chi@healthtech.com

www.healthtech.com

 

 
Print this page
Send to a friend
   
spacer
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>


News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement